View in EDS HTML Full Text PDF Full Text

Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial.

Saved in:
Bibliographic Details
Title: Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial.
Authors: McIlroy G; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK. g.w.mcilroy.1@bham.ac.uk., Gaskell C; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Jackson A; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Yafai E; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Tasker R; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Thomas C; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Fox S; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Boucher R; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Ghebretinsea F; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK., Harrison C; Department of Clinical Haematology, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London, UK., Mead AJ; Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, NIHR, Biomedical Research Centre, University of Oxford, Oxford, UK., McMullin MF; Centre for Medical Education, Queen's University Belfast, Belfast City Hospital, Lisburn Road, Belfast, UK.
Source: BMC cancer [BMC Cancer] 2025 Jan 10; Vol. 25 (1), pp. 56. Date of Electronic Publication: 2025 Jan 10.
Publication Type: Clinical Trial Protocol; Journal Article
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39789479
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22McIlroy+G%22">McIlroy G</searchLink>; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK. g.w.mcilroy.1@bham.ac.uk.<br /><searchLink fieldCode="AU" term="%22Gaskell+C%22">Gaskell C</searchLink>; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.<br /><searchLink fieldCode="AU" term="%22Jackson+A%22">Jackson A</searchLink>; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.<br /><searchLink fieldCode="AU" term="%22Yafai+E%22">Yafai E</searchLink>; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.<br /><searchLink fieldCode="AU" term="%22Tasker+R%22">Tasker R</searchLink>; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.<br /><searchLink fieldCode="AU" term="%22Thomas+C%22">Thomas C</searchLink>; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.<br /><searchLink fieldCode="AU" term="%22Fox+S%22">Fox S</searchLink>; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.<br /><searchLink fieldCode="AU" term="%22Boucher+R%22">Boucher R</searchLink>; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.<br /><searchLink fieldCode="AU" term="%22Ghebretinsea+F%22">Ghebretinsea F</searchLink>; Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.<br /><searchLink fieldCode="AU" term="%22Harrison+C%22">Harrison C</searchLink>; Department of Clinical Haematology, Guy's and St Thomas' National Health Service (NHS) Foundation Trust, London, UK.<br /><searchLink fieldCode="AU" term="%22Mead+AJ%22">Mead AJ</searchLink>; Medical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, NIHR, Biomedical Research Centre, University of Oxford, Oxford, UK.<br /><searchLink fieldCode="AU" term="%22McMullin+MF%22">McMullin MF</searchLink>; Centre for Medical Education, Queen's University Belfast, Belfast City Hospital, Lisburn Road, Belfast, UK.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100967800%22">BMC cancer</searchLink> [BMC Cancer] 2025 Jan 10; Vol. 25 (1), pp. 56. <i>Date of Electronic Publication: </i>2025 Jan 10.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial Protocol; Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BioMed+Central%22">BioMed Central </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100967800 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1471-2407 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214712407%22">14712407 </searchLink><i>NLM ISO Abbreviation: </i>BMC Cancer <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39789479
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s12885-024-13383-3
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 56
    Titles:
      – TitleFull: Fedratinib combined with ropeginterferon alfa-2b in patients with myelofibrosis (FEDORA): study protocol for a multicentre, open-label, Bayesian phase II trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: McIlroy G
      – PersonEntity:
          Name:
            NameFull: Gaskell C
      – PersonEntity:
          Name:
            NameFull: Jackson A
      – PersonEntity:
          Name:
            NameFull: Yafai E
      – PersonEntity:
          Name:
            NameFull: Tasker R
      – PersonEntity:
          Name:
            NameFull: Thomas C
      – PersonEntity:
          Name:
            NameFull: Fox S
      – PersonEntity:
          Name:
            NameFull: Boucher R
      – PersonEntity:
          Name:
            NameFull: Ghebretinsea F
      – PersonEntity:
          Name:
            NameFull: Harrison C
      – PersonEntity:
          Name:
            NameFull: Mead AJ
      – PersonEntity:
          Name:
            NameFull: McMullin MF
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 10
              M: 01
              Text: 2025 Jan 10
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1471-2407
          Numbering:
            – Type: volume
              Value: 25
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: BMC cancer
              Type: main
ResultId 1